[go: up one dir, main page]

PE20230495A1 - Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer - Google Patents

Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Info

Publication number
PE20230495A1
PE20230495A1 PE2022002801A PE2022002801A PE20230495A1 PE 20230495 A1 PE20230495 A1 PE 20230495A1 PE 2022002801 A PE2022002801 A PE 2022002801A PE 2022002801 A PE2022002801 A PE 2022002801A PE 20230495 A1 PE20230495 A1 PE 20230495A1
Authority
PE
Peru
Prior art keywords
alpha
domain
cancer
vaccination
mica
Prior art date
Application number
PE2022002801A
Other languages
English (en)
Inventor
Kai Wucherpfennig
Soumya Badrinath
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of PE20230495A1 publication Critical patent/PE20230495A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion proporciona composiciones y metodos para tratar cancer en un sujeto al provocar una respuesta inmune contra un polipeptido del dominio alfa 3 de MIC
PE2022002801A 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer PE20230495A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US201662422454P 2016-11-15 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Publications (1)

Publication Number Publication Date
PE20230495A1 true PE20230495A1 (es) 2023-03-23

Family

ID=57590885

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022002801A PE20230495A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer
PE2018001072A PE20181158A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018001072A PE20181158A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Country Status (24)

Country Link
US (3) US10993971B2 (es)
EP (1) EP3383426A1 (es)
JP (3) JP7099956B2 (es)
KR (1) KR20180088458A (es)
CN (1) CN108770343A (es)
AU (3) AU2016362597C1 (es)
BR (1) BR112018010705A8 (es)
CA (1) CA3005910A1 (es)
CL (3) CL2018001470A1 (es)
CO (1) CO2018006642A2 (es)
CR (2) CR20180350A (es)
CU (2) CU24609B1 (es)
EA (1) EA201891287A1 (es)
IL (1) IL259490A (es)
MX (2) MX2018006785A (es)
MY (1) MY199248A (es)
NZ (1) NZ742663A (es)
PE (2) PE20230495A1 (es)
PH (1) PH12018501170A1 (es)
RU (2) RU2747296C2 (es)
SG (1) SG11201804597TA (es)
TN (1) TN2018000187A1 (es)
WO (1) WO2017096374A1 (es)
ZA (1) ZA202204223B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
WO2019195316A1 (en) 2018-04-03 2019-10-10 Sanofi Ferritin proteins
AU2019247034B2 (en) 2018-04-03 2025-12-11 Sanofi Antigenic respiratory syncytial virus polypeptides
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
FI920131A7 (fi) 1989-07-14 1992-01-13 American Cyanamid Co Sytokiini- ja hormonikantajia konjugaattirokotteita varten
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
DK0942983T4 (en) 1996-10-31 2014-12-01 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
HU229968B1 (hu) 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
CA2776522C (en) 2001-10-01 2015-02-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
AU2003228962A1 (en) 2002-05-10 2003-11-11 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US20090104170A1 (en) 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011074573A1 (ja) 2009-12-18 2011-06-23 花王株式会社 メソポーラスシリカ粒子の製造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
PE20142361A1 (es) 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
SG11201404177PA (en) 2012-02-07 2014-08-28 Innate Pharma Mica binding agents
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
NZ629816A (en) 2013-03-15 2017-07-28 Dana Farber Cancer Inst Inc Therapeutic peptides
JP6518199B6 (ja) * 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
EP3116903A2 (en) * 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Also Published As

Publication number Publication date
PE20181158A1 (es) 2018-07-19
US10993971B2 (en) 2021-05-04
JP2022130623A (ja) 2022-09-06
AU2016362597B2 (en) 2022-02-17
RU2018123307A (ru) 2020-01-13
AU2016362597A1 (en) 2018-06-07
CR20230116A (es) 2023-05-05
CN108770343A (zh) 2018-11-06
WO2017096374A1 (en) 2017-06-08
SG11201804597TA (en) 2018-06-28
RU2018123307A3 (es) 2020-04-20
EA201891287A1 (ru) 2018-11-30
US20180353581A1 (en) 2018-12-13
AU2016362597C1 (en) 2022-05-26
BR112018010705A8 (pt) 2019-02-26
CL2023003217A1 (es) 2024-06-28
PH12018501170A1 (en) 2019-01-21
TN2018000187A1 (en) 2019-10-04
CA3005910A1 (en) 2017-06-08
CO2018006642A2 (es) 2018-07-10
CU20180050A7 (es) 2018-11-06
US20250064863A1 (en) 2025-02-27
JP7099956B2 (ja) 2022-07-12
RU2747296C2 (ru) 2021-05-04
AU2022201940B2 (en) 2025-05-08
AU2025213685A1 (en) 2025-08-28
AU2022201940A1 (en) 2022-04-14
EP3383426A1 (en) 2018-10-10
ZA202204223B (en) 2023-12-20
JP2018536002A (ja) 2018-12-06
NZ742663A (en) 2023-02-24
CU20210061A7 (es) 2022-02-04
MX2022010194A (es) 2022-09-19
JP2024177207A (ja) 2024-12-19
BR112018010705A2 (pt) 2018-11-21
IL259490A (en) 2018-07-31
JP7564842B2 (ja) 2024-10-09
CL2021001256A1 (es) 2021-12-31
RU2021109510A (ru) 2021-04-16
CR20180350A (es) 2018-10-02
US20210299186A1 (en) 2021-09-30
CU24609B1 (es) 2022-06-06
MX2018006785A (es) 2018-11-09
CL2018001470A1 (es) 2018-12-21
MY199248A (en) 2023-10-23
KR20180088458A (ko) 2018-08-03

Similar Documents

Publication Publication Date Title
CL2023003217A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX369921B (es) Tratamiento de la hgna y ehna.
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2017013802A (es) Métodos para tratar el cáncer.
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
TW201613587A (en) Medical treatments based on anamorelin
MX386458B (es) Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.
PH12016501838A1 (en) Compounds and their methods of use
BR112019004102A2 (pt) imunoterapia para poliomavírus
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.
HK1262082A1 (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer